
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings is a rapidly growing market leader in rare-disease testing lab services, with expertise in whole-exome and whole-genome sequencing. The company has a positive outlook due to its strong focus on pediatric and rare-disease diagnostics and its strategy to advance precision medicine. Despite a recent tough quarterly update and lowered guidance, the company's potential for growth and investment in expanding its sales force and acquisitions keep the analyst positive on the stock, with a "Buy" rating and a lowered price target of $70.
Bears say
GeneDx Holdings is expected to experience a short-term headwind in revenue due to the shift towards genome sequencing, but a new policy put in place by Carelon is likely to increase average selling price by $100 by H2 2027, potentially offsetting the initial impact. The launch of new tests and the rollout of newborn screening could also drive growth in the future, but it will take a few more years for these initiatives to take full effect. However, the recent Q1 miss and lowered guidance for 2026 suggest potential issues with forecasting and guidance, which could negatively impact the company's performance in the long term.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares